Interim report January – September 2023: STRONG MARGINS DESPITE WEAKER GROWTH
THIRD QUARTER 2023 (JUL – SEP)
Net sales amounted to SEK 210.2 million (205.1), an increase of 3 percent compared with the corresponding period in the preceding year. The previous year’s revenue included the large US order which was received in the second quarter of 2022, of SEK 39.4 million.
License revenue amounted to SEK 55.5 million (40.4) and accounted for 26 percent of net sales (20).
Operating profit amounted to SEK 50.7 million (42.7).
Net profit amounted to SEK 47.4 million (28.5), corresponding to earnings per share of SEK 0.93 (0.56).
Cash flow from operating activities amounted to SEK 53.1 million (9.5). As at September 30, 2023, cash and cash equivalents amounted to SEK 606.1 million (370.1).
FIRST NINE MONTHS OF 2023 (JAN – SEP)
Net sales amounted to SEK 655.6 million (552.4), an increase of 19 percent compared with the corresponding period in the preceding year.
Operating profit amounted to SEK 151.5 million (101.3).
Net profit amounted to SEK 136.0 million (71.5), corresponding to earnings per share of SEK 2.67 (1.41).
Cash flow from operating activities amounted to SEK 198.7 million (50.9).
Gothenburg, Sweden, November 9, 2023
Surgical Science Sweden AB (publ)
This report, in its entirety, is available through the attachment or via:
This is a translation of the Swedish version of the interim report. When in doubt, the Swedish wording prevails.